GlassScriptPhysician profile
Gail D Herman
NPI 1457301871
$5,285.39
in general payments reported to CMS, 2019-2025
32 companies · $547 in 2025
The $547 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $570 · 2021: $937 · 2022: $720 · 2023: $1,025 · 2024: $803 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,374.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,551.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $531.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $456.63 | 2019-2025 | |
| Pfizer INC. | $449.53 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $265.01 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.78 | 2019-2023 | Jardiance |
| Amgen INC. | $206.88 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $199.87 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $182.88 | 2021-2023 | Injectafer |
| Amarin Pharma, INC. | $169.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $153.56 | 2019-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $99.71 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $99.48 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $82.15 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.22 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.54 | 2019 | |
| Sumitomo Pharma America, INC. | $52.28 | 2024 | Gemtesa |
| Exact Sciences Corporation | $45.12 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $42.01 | 2023 | Freestyle Libre 2, Eterna, Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $37.83 | 2023 | Pascal |
| Ironwood Pharmaceuticals, INC | $37.66 | 2024 | |
| Allergan, INC. | $34.30 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $27.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.14 | 2019 | |
| Esperion Therapeutics, INC. | $21.05 | 2021 | |
| Genentech USA, INC. | $19.01 | 2021 | |
| Mylan Specialty L.P. | $18.86 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.93 | 2025 | Zoryve |
| Amag Pharmaceuticals, INC. | $15.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.26 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.56 | 2023 | Quviviq |
| Astellas Pharma US INC | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.